Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 429,193
  • Shares Outstanding, K 28,863
  • Annual Sales, $ 65,320 K
  • Annual Income, $ -81,890 K
  • EBIT $ -85 M
  • EBITDA $ -80 M
  • 60-Month Beta 0.96
  • Price/Sales 6.51
  • Price/Cash Flow N/A
  • Price/Book 4.87

Options Overview Details

View History
  • Implied Volatility 142.03% (+28.45%)
  • Historical Volatility 42.63%
  • IV Percentile 56%
  • IV Rank 38.71%
  • IV High 273.66% on 03/17/25
  • IV Low 58.87% on 06/09/25
  • Expected Move (DTE 3) 0.04 (0.29%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 123
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 3,007
  • Open Int (30-Day) 3,032
  • Expected Range 14.79 to 14.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.54
  • Number of Estimates 2
  • High Estimate -0.53
  • Low Estimate -0.54
  • Prior Year -1.05
  • Growth Rate Est. (year over year) +48.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.80 +26.27%
on 11/18/25
15.20 -1.97%
on 12/15/25
+2.84 (+23.55%)
since 11/14/25
3-Month
7.05 +111.35%
on 09/29/25
15.34 -2.87%
on 09/29/25
+7.45 (+100.00%)
since 09/16/25
52-Week
4.09 +264.30%
on 04/09/25
15.34 -2.87%
on 09/29/25
+8.59 (+136.13%)
since 12/16/24

Most Recent Stories

More News
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

ENTA : 14.93 (+0.40%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic...

ENTA : 14.93 (+0.40%)
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced...

ENTA : 14.93 (+0.40%)
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeekâ„¢ 2025

Zelicapavir Results in Shortened Symptom Duration in Pediatric Patients EDP-323 is Highly Effective in a Post-Exposure Prophylaxis Setting

ENTA : 14.93 (+0.40%)
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeekâ„¢ 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced...

ENTA : 14.93 (+0.40%)
Enanta Pharmaceuticals Announces Public Stock Offering

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Enanta Pharmaceuticals...

ENTA : 14.93 (+0.40%)
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that it has...

ENTA : 14.93 (+0.40%)
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an...

ENTA : 14.93 (+0.40%)
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an...

ENTA : 14.93 (+0.40%)
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥75 ...

ENTA : 14.93 (+0.40%)

Business Summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown,...

See More

Key Turning Points

3rd Resistance Point 16.12
2nd Resistance Point 15.66
1st Resistance Point 15.26
Last Price 14.93
1st Support Level 14.41
2nd Support Level 13.95
3rd Support Level 13.56

See More

52-Week High 15.34
Last Price 14.93
Fibonacci 61.8% 11.04
Fibonacci 50% 9.72
Fibonacci 38.2% 8.39
52-Week Low 4.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar